Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda Pharmaceuticals Inc.

www.vandapharma.com

Latest From Vanda Pharmaceuticals Inc.

US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics

BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.

Intellectual Property Legal Issues

Vanda Puts Dog Studies In Spotlight In Suit Challenging FDA Clinical Hold

Vanda seeks court order requiring US FDA to lift partial clinical hold on its gastroparesis treatment tradipitant; calls on drug makers to oppose agency's animal research policy, saying it requires unjustified killing of dogs.

Legal Issues Clinical Trials

Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action

A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.

Intellectual Property Legal Issues

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vanda Pharmaceuticals Inc.
  • Senior Management
  • Mihael H Polymeropoulos, MD, Pres. & CEO
    James Kelly, EVP, CFO & Treasurer
    Gunther Birznieks, SVP, Bus. Dev.
    Deepak Phadke, PhD, VP, Manufacturing
    Gian Piero Reverberi, SVP, Chief Commercial Officer
  • Contact Info
  • Vanda Pharmaceuticals Inc.
    Phone: (202) 734-3400
    2200 Pennsylvania Ave. NW
    Ste. 300E
    Washington, DC 20037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register